Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder
Authors:
- Lucette A. CysiqueLCLucette A. Cysique
- Krista J. SiefriedKSKrista J. Siefried
- Joga ChagantiJCJoga Chaganti
- Kirsten J. MoffatKMKirsten J. Moffat
- Bruce J. BrewBBBruce J. Brew
- 20 February 2016
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 30 (4) , 591-600
Abstract
To investigate whether intensification of combined antiretroviral therapy (cART) with the CC chemokine receptor type 5 (CCR5) entry inhibitor maraviroc leads to improvement in global neurocognitive functioning in virally suppressed men with HIV-associated neurocognitive disorder (HAND). Prospective, double observer-blinded, open-label pilot randomized-controlled trial. Participants were randomized to remain on their existing cART regimen (control arm; n = 8) or receive maraviroc-intensification (maraviroc arm; n = 9). Participants completed a five-domain neuropsychological battery at baseline, 6- and 12-month visits. Raw scores were transformed into age-corrected z-scores and averaged into a global z-score. Single voxel (H)-magnetic resonance spectroscopy (MRS) major cerebral metabolite concentrations were collected at baseline and 12 months in the basal ganglia and frontal white matter and quantified using jMRUI. Neuroinflammatory biomarkers cerebrospinal fluid neopterin and β2-microglobulin were also measured. Fourteen of the 17 participants completed the study: nine maraviroc arm and five control. We found medium to large effect sizes in favour of improved global neurocognitive performance in the maraviroc arm over time {arm*time interaction: P < 0.05; 6 month: [β=-0.10, standard error (SE)= 0.04, 90% confidence interval (90%CI)= -0.18,.03; P < 0.03] yielding a large effect-size d = 0.77 (90%CI = -0.19,1.71); 12 month: [β=-0.01; SE = 0.05; 90%CI = -0.09, 0.06; P < 0.77] yielding a moderate effect-size d = 0.55 (90%CI = -0.47,1.55)}. No treatment-related changes were detected for H-MRS metabolites or cerebrospinal fluid biomarkers. This pilot study provides feasibility, tolerability, proof-of-concept and preliminary evidence for clinically relevant neurocognitive improvement in cART enhancement with maraviroc in virally suppressed HAND patients. Lack of concomitant brain metabolite and biomarker change may be related to complex dynamics of brain repair.Keywords
This publication has 48 references indexed in Scilit:
- Facial emotional processing in HIV infection: Relation to neurocognitive and neuropsychiatric status.Neuropsychology, 2012
- Cardiovascular risk factors and carotid intima‐media thickness are associated with lower cognitive performance in HIV‐infected patientsHIV Medicine, 2012
- Cognitive Performance Related to HIV-1-Infected MonocytesThe Journal of Neuropsychiatry and Clinical Neurosciences, 2012
- Failure to clear intra-monocyte HIV infection linked to persistent neuropsychological testing impairment after first-line combined antiretroviral therapyJournal of NeuroVirology, 2011
- Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future researchBMC Neurology, 2011
- Normative data and validation of a regression based summary score for assessing meaningful neuropsychological changeJournal of Clinical and Experimental Neuropsychology, 2011
- HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapyNeurology, 2010
- Brain metabolism and cognitive impairment in HIV infection: a 3-T magnetic resonance spectroscopy studyMagnetic Resonance Imaging, 2010
- Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapyNeurology, 2009
- Tissue-Specific Sequence Alterations in the Human Immunodeficiency Virus Type 1 Envelope Favoring CCR5 Usage Contribute to Persistence of Dual-Tropic Virus in the BrainJournal of Virology, 2009